- Home
- JAZZ vs CHWY Comparison
JAZZ vs CHWY Comparison
Compare JAZZ & CHWY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JAZZ | CHWY |
|---|---|---|
| Founded | 2003 | 2010 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Catalog/Specialty Distribution |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 11.0B |
| IPO Year | 2007 | 2019 |
Fundamental Metrics
Financial Performance| Metric | JAZZ | CHWY |
|---|---|---|
| Price | $200.42 | $26.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 24 |
| Target Price | ★ $217.57 | $43.52 |
| AVG Volume (30 Days) | 849.8K | ★ 6.7M |
| Earning Date | 05-05-2026 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.52 |
| Revenue | $1,618,693,000.00 | ★ $12,601,500,000.00 |
| Revenue This Year | $6.22 | $10.70 |
| Revenue Next Year | $7.68 | $7.84 |
| P/E Ratio | ★ N/A | $49.36 |
| Revenue Growth | N/A | ★ 6.24 |
| 52 Week Low | $105.00 | $22.74 |
| 52 Week High | $207.48 | $48.62 |
Technical Indicators
Market Signals| Indicator | JAZZ | CHWY |
|---|---|---|
| Relative Strength Index (RSI) | 57.01 | 48.86 |
| Support Level | $159.78 | $24.75 |
| Resistance Level | $207.48 | $27.77 |
| Average True Range (ATR) | 5.42 | 1.20 |
| MACD | -0.27 | -0.14 |
| Stochastic Oscillator | 53.40 | 29.67 |
Price Performance
Historical ComparisonAbout JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About CHWY Chewy Inc.
Chewy is the largest e-commerce petcare retailer in the US, generating $11.9 billion in fiscal 2024 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a stand-alone company in 2019 after spending time developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods like crates, leashes, and bowls.